Related Experiment Video

Updated: Jun 16, 2026

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions
09:41

Quantification of Monocyte Transmigration and Foam Cell Formation from Individuals with Chronic Inflammatory Conditions

Published on: October 17, 2017

Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes

Elisabetta Mandosi1, Mara Fallarino, Alessandra Gatti

  • 1Department of Clinical Sciences, Sapienza University of Rome, Rome, Italy.

Journal of Atherosclerosis and Thrombosis
|February 6, 2010
PubMed

Insights

Atorvastatin therapy in type 2 diabetes patients reduced CD36 scavenger receptor expression and inflammation markers. This suggests atorvastatin offers anti-atherogenic benefits beyond cholesterol reduction.

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Immunology

Background:

  • Type 2 diabetes is a significant risk factor for cardiovascular disease.
  • Statins, including atorvastatin, are crucial for reducing cardiovascular events in diabetic patients.
  • The cardiovascular benefits of statins may extend beyond lipid-lowering effects.

Purpose of the Study:

  • To investigate the impact of atorvastatin on CD36 scavenger receptor expression in monocytes.
  • To assess changes in nuclear factor-kappaB (NFkappaB) levels and inflammatory markers (CRP, TNF-alpha) in diabetic patients treated with atorvastatin.

Main Methods:

  • Twenty-two type 2 diabetes patients received 8 weeks of atorvastatin (20 mg/day).
  • Blood samples were collected at baseline and post-treatment for analysis of lipids, HbA1c, CRP, and monocyte isolation.
  • Monocyte CD36 expression, NFkappaB localization, and TNF-alpha production were measured.

Main Results:

  • Atorvastatin significantly improved lipid profiles, increasing HDL and decreasing total and LDL cholesterol.
  • A notable reduction in CD36 surface protein expression on monocytes was observed post-treatment.
  • Atorvastatin therapy led to decreased nuclear NFkappaB levels and reduced TNF-alpha production in activated monocytes.

Conclusions:

  • Atorvastatin therapy demonstrates anti-atherogenic and anti-inflammatory effects in type 2 diabetic patients.
  • These effects are mediated by reducing CD36 expression and modulating NFkappaB and TNF-alpha pathways.
  • Atorvastatin offers potential therapeutic benefits for cardiovascular disease prevention in diabetes beyond lipid modification.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...